A Phase 1b Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone (DRd) in Japanese Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation
Phase of Trial: Phase I
Latest Information Update: 11 Dec 2017
At a glance
- Drugs Daratumumab (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Janssen Pharmaceutical KK
- 06 Dec 2017 Planned End Date changed from 15 Apr 2020 to 1 Apr 2020.
- 06 Dec 2017 Planned primary completion date changed from 15 Apr 2020 to 1 Apr 2020.
- 30 Sep 2016 Status changed from not yet recruiting to recruiting.